Vanda Pharmaceuticals announced the publication of a pivotal phase III study on imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP), in the New England Journal of Medicine Evidence. This study supports Vanda's Biologics License Application (BLA) submitted to the FDA, with a target decision date of December 12, 2026. Imsidolimab is a monoclonal antibody targeting IL-36 receptor signaling, aimed at treating the rare GPP condition. Regulatory and patent protections for the drug are expected to last into the late 2030s, positioning Vanda for long-term market exclusivity if approved.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
